Matches in SemOpenAlex for { <https://semopenalex.org/work/W65760870> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W65760870 endingPage "72" @default.
- W65760870 startingPage "166" @default.
- W65760870 abstract "The asymptomatic ischemic cerebrovascular disorders (AICVD) is an early manifestation of cerebrovascular disease. It is also known as latent insufficiency of the cerebrovascular circulation or as asymptomatic cerebrovascular disorders. Recently, the term subclinical disease, detected noninvasively, has been introduced by American Heart Association. The diagnosis is based on the following criteria: evidence of vascular risk factors; episodic nonspecific complaints without any focal cerebral symptoms; mild cognitive deficit, detected by neuropsychological tests; carotid ultrasonography often shows intimal-medial thickening, atherosclerotic plaques and carotid stenosis; CT and MRI occasionally reveal silent cerebral infarctions, white matter hyperintensities or cerebral atrophy; regional hypoperfusion above the ischemic threshold is also seen by rCBF measurements. Treatment of the AICVD, modifying the vascular risk factors and using neuroprotective agents, should be the cornerstone of primary prevention of ischemic stroke and cognitive decline, caused by cerebrovascular disorders. Vinpocetine has been found to interfere with various stages of the ischemic cascade: ATP depletion, activation of voltage-sensitive Na(+)- and Ca(++)-channels, glutamate and free radicals release. The inhibition of the voltage-sensitive Na(+)-channels appears to be especially relevant to the neuroprotective effect of vinpocetine. Pronounced antioxidant activity of the drug could also contribute to the neuroprotection. PET studies in primates and man showed that 11C labelled vinpocetine passes the blood-brain barrier rapidly. Heterogeneous brain distribution of the compound was observed mainly in the thalamus, basal ganglia, occipital, parietal and temporal cortex, regions which are closely related to the cognitive functions. PET studies in chronic ischemic stroke patients revealed favourable effects of vinpocetine on rCBF and glucose metabolism in the thalamus, basal ganglia and primary visual cortex. It seems, vinpocetine, affecting the multiple mechanisms of the AICVD, could be of benefit for the treatment in this early stage of cerebrovascular disease. Vinpocetine may also become a new therapeutic approach to prophylactic neuroprotection in patients at high risk of ischemic stroke." @default.
- W65760870 created "2016-06-24" @default.
- W65760870 creator A5090278294 @default.
- W65760870 date "2003-05-20" @default.
- W65760870 modified "2023-09-23" @default.
- W65760870 title "Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine." @default.
- W65760870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12861957" @default.
- W65760870 hasPublicationYear "2003" @default.
- W65760870 type Work @default.
- W65760870 sameAs 65760870 @default.
- W65760870 citedByCount "5" @default.
- W65760870 countsByYear W657608702016 @default.
- W65760870 countsByYear W657608702019 @default.
- W65760870 countsByYear W657608702023 @default.
- W65760870 crossrefType "journal-article" @default.
- W65760870 hasAuthorship W65760870A5090278294 @default.
- W65760870 hasConcept C126322002 @default.
- W65760870 hasConcept C126838900 @default.
- W65760870 hasConcept C127413603 @default.
- W65760870 hasConcept C143409427 @default.
- W65760870 hasConcept C146638467 @default.
- W65760870 hasConcept C15744967 @default.
- W65760870 hasConcept C157767197 @default.
- W65760870 hasConcept C164705383 @default.
- W65760870 hasConcept C169760540 @default.
- W65760870 hasConcept C25498285 @default.
- W65760870 hasConcept C2777910003 @default.
- W65760870 hasConcept C2778788455 @default.
- W65760870 hasConcept C2780645631 @default.
- W65760870 hasConcept C42219234 @default.
- W65760870 hasConcept C71924100 @default.
- W65760870 hasConcept C78519656 @default.
- W65760870 hasConcept C98274493 @default.
- W65760870 hasConceptScore W65760870C126322002 @default.
- W65760870 hasConceptScore W65760870C126838900 @default.
- W65760870 hasConceptScore W65760870C127413603 @default.
- W65760870 hasConceptScore W65760870C143409427 @default.
- W65760870 hasConceptScore W65760870C146638467 @default.
- W65760870 hasConceptScore W65760870C15744967 @default.
- W65760870 hasConceptScore W65760870C157767197 @default.
- W65760870 hasConceptScore W65760870C164705383 @default.
- W65760870 hasConceptScore W65760870C169760540 @default.
- W65760870 hasConceptScore W65760870C25498285 @default.
- W65760870 hasConceptScore W65760870C2777910003 @default.
- W65760870 hasConceptScore W65760870C2778788455 @default.
- W65760870 hasConceptScore W65760870C2780645631 @default.
- W65760870 hasConceptScore W65760870C42219234 @default.
- W65760870 hasConceptScore W65760870C71924100 @default.
- W65760870 hasConceptScore W65760870C78519656 @default.
- W65760870 hasConceptScore W65760870C98274493 @default.
- W65760870 hasIssue "5-6" @default.
- W65760870 hasLocation W657608701 @default.
- W65760870 hasOpenAccess W65760870 @default.
- W65760870 hasPrimaryLocation W657608701 @default.
- W65760870 hasRelatedWork W1988627560 @default.
- W65760870 hasRelatedWork W1998808508 @default.
- W65760870 hasRelatedWork W2031487366 @default.
- W65760870 hasRelatedWork W2092060399 @default.
- W65760870 hasRelatedWork W2107831372 @default.
- W65760870 hasRelatedWork W2140100621 @default.
- W65760870 hasRelatedWork W2160930136 @default.
- W65760870 hasRelatedWork W2887005291 @default.
- W65760870 hasRelatedWork W3012054679 @default.
- W65760870 hasRelatedWork W65760870 @default.
- W65760870 hasVolume "56" @default.
- W65760870 isParatext "false" @default.
- W65760870 isRetracted "false" @default.
- W65760870 magId "65760870" @default.
- W65760870 workType "article" @default.